Senores Pharmaceuticals Latest Updates

Financial and Operational Highlights Investment in US Subsidiary: Senores Pharmaceuticals announced a $2 million investment in its wholly-owned US subsidiary, Senores Pharmaceuticals Inc. (SPI), through a rights issue. The capital infusion is intended to strengthen the working capital of the US subsidiary and support its growth, which has seen its turnover more than triple in the last fiscal year. Strong Q1 FY26 Performance: The company started the fiscal year on a strong note, with a total income of ₹138 crore in Q1 FY26, a 72% increase year-on-year. Profit after tax (PAT) almost doubled, growing by 95% year-on-year to ₹21.2 crore. This growth was driven by a robust performance in both the regulated and emerging markets, as well as its contract manufacturing (CDMO/CMO) business. Product and Portfolio Expansion US FDA Approvals: In January 2025, Senores Pharmaceuticals received final approval from the United States Food and Drug Administration (USFDA) to market Metoprolol Tartrate and Hydrochlorothiazide tablets for the treatment of hypertension. ANDA Acquisition: The company, through its US subsidiary, acquired the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets from Wockhardt in May 2025. This acquisition is in line with the company's strategy of expanding its product portfolio in the US market. Product Launches: During Q1 FY26, Senores launched two new ANDA products in the regulated markets and received four new ANDA approvals. The company's pipeline includes 57 products, with 37 products having a "Competitive Generic Therapy" (CGT) designation, which offers a period of market exclusivity.